Tvardi Therapeutics (TVRD) Change in Accured Expenses: 2012-2024
Historic Change in Accured Expenses for Tvardi Therapeutics (TVRD) over the last 13 years, with Dec 2024 value amounting to -$21.4 million.
- Tvardi Therapeutics' Change in Accured Expenses fell 73.79% to $1.2 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$3.0 million, marking a year-over-year decrease of 148.32%. This contributed to the annual value of -$21.4 million for FY2024, which is 754.63% down from last year.
- As of FY2024, Tvardi Therapeutics' Change in Accured Expenses stood at -$21.4 million, which was down 754.63% from $3.3 million recorded in FY2023.
- Tvardi Therapeutics' Change in Accured Expenses' 5-year high stood at $5.7 million during FY2022, with a 5-year trough of -$21.4 million in FY2024.
- For the 3-year period, Tvardi Therapeutics' Change in Accured Expenses averaged around -$4.2 million, with its median value being $3.3 million (2023).
- As far as peak fluctuations go, Tvardi Therapeutics' Change in Accured Expenses skyrocketed by 656.76% in 2022, and later slumped by 754.63% in 2024.
- Over the past 5 years, Tvardi Therapeutics' Change in Accured Expenses (Yearly) stood at -$2.8 million in 2020, then surged by 63.36% to -$1.0 million in 2021, then skyrocketed by 656.76% to $5.7 million in 2022, then plummeted by 42.33% to $3.3 million in 2023, then tumbled by 754.63% to -$21.4 million in 2024.